55 results
Page 2 of 3
424B5
otrhcw
25 Apr 22
Prospectus supplement for primary offering
4:03pm
8-K
EX-99.1
x3qt15xzr
29 Mar 22
Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors
8:11am
8-K
EX-99.1
s82i0n 4i
17 Mar 22
Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
4:11pm
8-K
EX-99.1
y5z19257fm7upswre35k
10 Nov 21
Nkarta Reports Third Quarter 2021 Financial Results and Business Update
4:14pm
8-K
EX-99.1
mvyzzc5k50taec52p
7 Oct 21
Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
4:09pm
424B5
nipnm5utai7thns 3l17
3 Sep 21
Prospectus supplement for primary offering
12:00am
S-3
2kto10vl sasfocusi
12 Aug 21
Shelf registration
5:04pm
8-K
EX-99.1
ch6bwpt6 f0mvc8f8q0h
12 Aug 21
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
4:19pm
8-K
EX-10.1
yqmlwhq7v7 uursaohw
14 Jul 21
Entry into a Material Definitive Agreement
7:07am
8-K
EX-99.1
xvlj3hy84snm6nsuaws
14 Jul 21
Entry into a Material Definitive Agreement
7:07am
8-K
EX-99.1
f61x6rjige5xvsgb
13 May 21
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
4:18pm
8-K
EX-99.1
coo s9oe5m
6 May 21
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
4:24pm
8-K
EX-99.1
goz3g6trr3
28 Apr 21
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
8:07am
DEF 14A
am2bey8 bjw
22 Apr 21
Definitive proxy
12:35pm